Pharmaceutical Market Trends Again Erupt, Pharm ETF Up 2%, Hengrui Pharmaceutical Continues to Create 4-Year New High! CXO Giants' Performance Soars, A-Share Largest Healthcare ETF Expected to Hit 10 Consecutive Ups!

July 29 morning, the A-share pharmaceutical market again erupts, with drug-making and healthcare companies rallying together.

The first domestic tracking pharmaceutical index ETF (562050) surged up to 2% during the day! With a massive $100 billion overseas single order as support, the core component stock Hengrui Pharmaceutical, which had risen by the previous trading day and continued to rise above 4%, with its market value reaching 43 billion yuan. Its net profit attributable to shareholders surged 101.9% year-on-year, with its revenue guidance revised upwards to 13%-17%.

CXO leaders drive the healthcare sector's upward trend, with Tage Pharmaceutical (300347) rising by over 10%, and Jiuzhou Pharmaceutical (603456) reaching its daily limit. The giants Pharming Concede rose by over 8%!

As for Pharming Concede, it released its 2025 semi-annual report: the company's revenue reached 208 billion yuan, up 20.6% year-on-year, and its net profit attributable to shareholders surged 101.9%. The company also declared a first-ever mid-term dividend of 10 billion yuan, with an expected full-year return of over 80 billion yuan for shareholders.

Analysts point out that as the CXO industry leader, Pharming Concede's impressive semi-annual report and revised guidance have confirmed that the medical industry is ripe for innovation cooperation. Although the development trend may have fluctuations, demand will only increase but not decrease.